Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes

Toshihide Kawai, Osamu Funae, Akira Shimada, Mitsuhisa Tabata, Takumi Hirata, Yoshihito Atsumi, Hiroshi Itoh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: We investigated whether or not "low dose" metformin could prevent weight gain induced by pioglitazone. Research Design and Methods: Sixty-nine patients with-type 2 diabetes received 500-750 mg metformin a day for 12 weeks as an observation period before the start of the intervention. After an observation period, inadequately controlled patients (hemoglobin Alc ≥7.5%, n=34) received additional treatment with 15 mg pioglitazone (+P, M+P group). The other patients (n= 35) continued metformin monotherapy (Met group). In addition, another group consisting of 28 patients treated with 15 mg pioglitazone alone (Pio group) was observed. Body mass index (BMI), as well as several clinical, parameters of glycemic control and lipid metabolism was compared before and after 24 weeks of intervention. Results: BMI increased significantly in the Pio group [24.0±3.8 vs. 24.8±4.3 kg/m2, (mean ± SD), p<0.001], but not in the M+P group (25.1±3.5 vs. 25.3±3.4 kg/m2, NS) and Met group (24.0±3.3 vs. 24.0±3.5 kg/m2, NS). In addition to improvement in glycemic control, a significant reduction in the atherogenic index of plasma (AIP), defined as log [TG ×0.0112/HDL-C ×0.025861, was observed in the Pio group (0.06±0.23 vs. -0.04±0.27, p<0.05) and M+P group (0.08±0.24 vs. -0.001±0.252, p<0.01), but not in the Met group. Conclusion: This study indicates potential benefits of the addition of pioglitazone to "low dose" metformin in terms of improvement of glucose and lipid metabolism without weight gain.

Original languageEnglish
Pages (from-to)1181-1188
Number of pages8
JournalInternal Medicine
Volume47
Issue number13
DOIs
Publication statusPublished - 2008

Fingerprint

pioglitazone
Metformin
Type 2 Diabetes Mellitus
Weight Gain
Lipid Metabolism
Body Mass Index
Observation
Hemoglobins
Research Design
Glucose

Keywords

  • Atherogenic index of plasma (AIP)
  • Combination therapy
  • Metformin
  • Pioglitazone
  • Weight gain

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Cite this

Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. / Kawai, Toshihide; Funae, Osamu; Shimada, Akira; Tabata, Mitsuhisa; Hirata, Takumi; Atsumi, Yoshihito; Itoh, Hiroshi.

In: Internal Medicine, Vol. 47, No. 13, 2008, p. 1181-1188.

Research output: Contribution to journalArticle

Kawai, Toshihide ; Funae, Osamu ; Shimada, Akira ; Tabata, Mitsuhisa ; Hirata, Takumi ; Atsumi, Yoshihito ; Itoh, Hiroshi. / Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. In: Internal Medicine. 2008 ; Vol. 47, No. 13. pp. 1181-1188.
@article{860733da8e6c4decbf04e5d4f6749e26,
title = "Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes",
abstract = "Objective: We investigated whether or not {"}low dose{"} metformin could prevent weight gain induced by pioglitazone. Research Design and Methods: Sixty-nine patients with-type 2 diabetes received 500-750 mg metformin a day for 12 weeks as an observation period before the start of the intervention. After an observation period, inadequately controlled patients (hemoglobin Alc ≥7.5{\%}, n=34) received additional treatment with 15 mg pioglitazone (+P, M+P group). The other patients (n= 35) continued metformin monotherapy (Met group). In addition, another group consisting of 28 patients treated with 15 mg pioglitazone alone (Pio group) was observed. Body mass index (BMI), as well as several clinical, parameters of glycemic control and lipid metabolism was compared before and after 24 weeks of intervention. Results: BMI increased significantly in the Pio group [24.0±3.8 vs. 24.8±4.3 kg/m2, (mean ± SD), p<0.001], but not in the M+P group (25.1±3.5 vs. 25.3±3.4 kg/m2, NS) and Met group (24.0±3.3 vs. 24.0±3.5 kg/m2, NS). In addition to improvement in glycemic control, a significant reduction in the atherogenic index of plasma (AIP), defined as log [TG ×0.0112/HDL-C ×0.025861, was observed in the Pio group (0.06±0.23 vs. -0.04±0.27, p<0.05) and M+P group (0.08±0.24 vs. -0.001±0.252, p<0.01), but not in the Met group. Conclusion: This study indicates potential benefits of the addition of pioglitazone to {"}low dose{"} metformin in terms of improvement of glucose and lipid metabolism without weight gain.",
keywords = "Atherogenic index of plasma (AIP), Combination therapy, Metformin, Pioglitazone, Weight gain",
author = "Toshihide Kawai and Osamu Funae and Akira Shimada and Mitsuhisa Tabata and Takumi Hirata and Yoshihito Atsumi and Hiroshi Itoh",
year = "2008",
doi = "10.2169/internalmedicine.47.0969",
language = "English",
volume = "47",
pages = "1181--1188",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "13",

}

TY - JOUR

T1 - Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes

AU - Kawai, Toshihide

AU - Funae, Osamu

AU - Shimada, Akira

AU - Tabata, Mitsuhisa

AU - Hirata, Takumi

AU - Atsumi, Yoshihito

AU - Itoh, Hiroshi

PY - 2008

Y1 - 2008

N2 - Objective: We investigated whether or not "low dose" metformin could prevent weight gain induced by pioglitazone. Research Design and Methods: Sixty-nine patients with-type 2 diabetes received 500-750 mg metformin a day for 12 weeks as an observation period before the start of the intervention. After an observation period, inadequately controlled patients (hemoglobin Alc ≥7.5%, n=34) received additional treatment with 15 mg pioglitazone (+P, M+P group). The other patients (n= 35) continued metformin monotherapy (Met group). In addition, another group consisting of 28 patients treated with 15 mg pioglitazone alone (Pio group) was observed. Body mass index (BMI), as well as several clinical, parameters of glycemic control and lipid metabolism was compared before and after 24 weeks of intervention. Results: BMI increased significantly in the Pio group [24.0±3.8 vs. 24.8±4.3 kg/m2, (mean ± SD), p<0.001], but not in the M+P group (25.1±3.5 vs. 25.3±3.4 kg/m2, NS) and Met group (24.0±3.3 vs. 24.0±3.5 kg/m2, NS). In addition to improvement in glycemic control, a significant reduction in the atherogenic index of plasma (AIP), defined as log [TG ×0.0112/HDL-C ×0.025861, was observed in the Pio group (0.06±0.23 vs. -0.04±0.27, p<0.05) and M+P group (0.08±0.24 vs. -0.001±0.252, p<0.01), but not in the Met group. Conclusion: This study indicates potential benefits of the addition of pioglitazone to "low dose" metformin in terms of improvement of glucose and lipid metabolism without weight gain.

AB - Objective: We investigated whether or not "low dose" metformin could prevent weight gain induced by pioglitazone. Research Design and Methods: Sixty-nine patients with-type 2 diabetes received 500-750 mg metformin a day for 12 weeks as an observation period before the start of the intervention. After an observation period, inadequately controlled patients (hemoglobin Alc ≥7.5%, n=34) received additional treatment with 15 mg pioglitazone (+P, M+P group). The other patients (n= 35) continued metformin monotherapy (Met group). In addition, another group consisting of 28 patients treated with 15 mg pioglitazone alone (Pio group) was observed. Body mass index (BMI), as well as several clinical, parameters of glycemic control and lipid metabolism was compared before and after 24 weeks of intervention. Results: BMI increased significantly in the Pio group [24.0±3.8 vs. 24.8±4.3 kg/m2, (mean ± SD), p<0.001], but not in the M+P group (25.1±3.5 vs. 25.3±3.4 kg/m2, NS) and Met group (24.0±3.3 vs. 24.0±3.5 kg/m2, NS). In addition to improvement in glycemic control, a significant reduction in the atherogenic index of plasma (AIP), defined as log [TG ×0.0112/HDL-C ×0.025861, was observed in the Pio group (0.06±0.23 vs. -0.04±0.27, p<0.05) and M+P group (0.08±0.24 vs. -0.001±0.252, p<0.01), but not in the Met group. Conclusion: This study indicates potential benefits of the addition of pioglitazone to "low dose" metformin in terms of improvement of glucose and lipid metabolism without weight gain.

KW - Atherogenic index of plasma (AIP)

KW - Combination therapy

KW - Metformin

KW - Pioglitazone

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=49649103582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649103582&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.47.0969

DO - 10.2169/internalmedicine.47.0969

M3 - Article

VL - 47

SP - 1181

EP - 1188

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 13

ER -